Cardiovascular Diseases among Patients with Cancer and Patients living with HIV

癌症患者和艾滋病毒感染者的心血管疾病

基本信息

  • 批准号:
    10546509
  • 负责人:
  • 金额:
    $ 12.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-01-02 至 2024-12-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract: Tomas Neilan MD MPH is a clinically-active cardiologist in the Division of Cardiology and Cardiovascular Imaging at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Over the last 10 years, Dr. Neilan’s research has focused on applying advanced imaging to two complementary areas, the cardiovascular toxicities associated with cancer therapies and heart failure among persons with HIV. Dr. Neilan’s extensive mentoring experience, publication and funding record, together with his current and planned research support, demonstrate his commitment and passion for POR and provide an excellent foundation to accomplish the goals and objectives of the K24 Award. The specific aims addressing the purpose of the K24 Award are: 1) To enable Dr. Neilan to dedicate 25% of his time to mentor junior clinical investigators based on already NIH funded projects; 2) To mentor junior clinical investigators from the T-32 program and the pool of residents, fellows, and junior faculty in Cardiology and Radiology with the goal to develop them into clinical researchers who can successfully compete for peer reviewed grants; and 3) To enable Dr. Neilan to consolidate a POR that combines innovative translational, clinical, and outcomes research in cardiovascular imaging and that provides an ideal environment to develop future leaders in clinical research. Dr. Neilan’s current leadership roles align well with this proposal. He is the Co-Director of the Cardiac MR CT PET Program, a clinical research program in cardiovascular imaging supported by the Division of Cardiology and the Department of Radiology, the Associate Director of the MGH T32 training grant in cardiovascular imaging, and the Director of the Cardio-Oncology Program in the Division of Cardiology. In addition to his roles, Dr. Neilan also has an unreserved commitment from the leadership of both Cardiology and Radiology providing a foundation that is ideal to successfully mentor junior clinical investigators and fulfill the purpose of the Award. The specific research aims of this grant stem from a significant body of work accomplished over the past few years and are all based on on-going NIH funded projects, except Aim 4 which is new research specifically supported by this grant: 1) STOP-CA – Testing in a randomized multicenter clinical trial the effect of statins on the reduction in left ventricular ejection fraction after anthracycline-based chemotherapy, 2) REPRIEVE-MR – Testing in a randomized multicenter clinical trial whether statins reduce myocardial fibrosis, myocardial steatosis and preserve cardiac function among persons living with HIV, 3) STOP-CA Fibrosis – where we apply novel MRI- based imaging techniques to provide insight into the role of myocardial fibrosis in the development of anthracycline-induced cardiotoxicity, and test the effect of statins on myocardial fibrosis after anthracyclines, and 4) Expanding our international registry to improve our limited understanding of the predictors, presentation, treatments and outcomes of patients presenting with myocarditis after immune checkpoint inhibitors (ICI’s).
项目摘要/摘要:Tomas Neilan MD MPH 是一位临床活跃的心脏病专家。 马萨诸塞州总医院心脏病学和心血管影像学副教授 哈佛医学院医学。在过去的 10 年里,Neilan 博士的研究重点是应用 对两个互补领域的先进成像,即与癌症治疗相关的心血管毒性 以及艾滋病毒感染者的心力衰竭。 Neilan 博士拥有丰富的指导经验、出版物和 资助记录以及他当前和计划的研究支持表明了他的承诺和 对 POR 的热情,为实现 K24 奖的目的和目标提供了良好的基础。 K24 奖的具体目标是: 1) 让 Neilan 博士贡献 25% 他根据 NIH 资助的项目指导初级临床研究人员; 2)指导后辈 来自 T-32 计划的临床研究人员以及心脏病学领域的住院医生、研究员和初级教员 和放射学,目标是将他们培养成能够成功竞争同行的临床研究人员 审查补助金; 3) 使 Neilan 博士能够巩固 POR,该 POR 结合了创新的转化、 心血管成像的临床和结果研究,并提供了理想的开发环境 临床研究的未来领导者。 Neilan 博士目前的领导角色与这一提议非常吻合。他是 心脏 MR CT PET 项目联席主任,该项目是心血管成像的临床研究项目 得到麻省总医院心脏病科和放射科副主任的支持 T32 心血管影像培训补助金,以及该科心脏肿瘤学项目主任 心脏病学。除了他的角色之外,内兰博士还得到了领导层的毫无保留的承诺 心脏病学和放射学为成功指导初级临床提供了理想的基础 调查员并实现奖项的目的。这项资助的具体研究目的源于 过去几年中完成的重要工作都是基于 NIH 持续资助的 项目,除了目标 4(这是本次拨款特别支持的新研究): 1) STOP-CA – 在随机多中心临床试验中测试他汀类药物对左心室减少的影响 蒽环类化疗后的心室射血分数,2) REPRIEVE-MR – 在 他汀类药物能否减少心肌纤维化、心肌脂肪变性和心肌梗死的随机多中心临床试验 保护 HIV 感染者的心脏功能,3) STOP-CA 纤维化 – 我们应用新型 MRI- 基于成像技术来深入了解心肌纤维化在心肌纤维化发展中的作用 蒽环类药物引起的心脏毒性,并测试他汀类药物对蒽环类药物后心肌纤维化的影响, 4) 扩大我们的国际登记册,以提高我们对预测因素、表述、 免疫检查点抑制剂(ICI)后出现心肌炎的患者的治疗和结果。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tomas G Neilan其他文献

Stress cardiac magnetic resonance imaging effectively reclassifies risk in patients with known or suspected stable coronary artery disease
  • DOI:
    10.1186/1532-429x-15-s1-p186
  • 发表时间:
    2013-01-30
  • 期刊:
  • 影响因子:
  • 作者:
    Jiazuo H Feng;Ravi Shah;Bobby Heydari;Venkatesh L Murthy;Siddique Abbasi;Tomas G Neilan;Ron ABlankstein;Marcelo Di Carli;Michael Jerosch-Herold;Raymond Y Kwong
  • 通讯作者:
    Raymond Y Kwong
Myocardial extracellular volume expansion in patients with hypertension
  • DOI:
    10.1186/1532-429x-15-s1-o110
  • 发表时间:
    2013-01-30
  • 期刊:
  • 影响因子:
  • 作者:
    Tomas G Neilan;Francois-Pierre Mongeon;Otavio R Coelho-Filho;Ravi Shah;Ciaran J McMullan;Siddique Abbasi;Eri Watanabe;Bobby Heydari;Ron Blankstein;Raymond Y Kwong;Michael Jerosch-Herold
  • 通讯作者:
    Michael Jerosch-Herold
The incidence and prognostic value of silent myocardial scar by late gadolinium enhancement in patients with atrial fibrillation
  • DOI:
    10.1186/1532-429x-15-s1-p259
  • 发表时间:
    2013-01-30
  • 期刊:
  • 影响因子:
  • 作者:
    Tomas G Neilan;Hoshang Farhad;Ravi Shah;Siddique Abbasi;Otavio R Coelho-Filho;John D Groarke;Ciaran J McMullan;Bobby Heydari;Michael L Steigner;Ron Blankstein;Michael Jerosch-Herold;Raymond Y Kwong
  • 通讯作者:
    Raymond Y Kwong
Diabetes remains an independent risk factor for adverse remodeling following acute myocardial infarction even with quantification of total infarct size and change in myocardial extracellular volume fraction by CMR
  • DOI:
    10.1186/1532-429x-15-s1-p185
  • 发表时间:
    2013-01-30
  • 期刊:
  • 影响因子:
  • 作者:
    Bobby Heydari;Ravi Shah;Siddique Abbasi;Jiazuo H Feng;Hoshang Farhad;Tomas G Neilan;Ron Blankstein;Rob J van der Geest;Shuaib Abdullah;Sanjeev Francis;Udo Hoffmann;Michael Jerosch-Herold;Raymond Y Kwong
  • 通讯作者:
    Raymond Y Kwong
Characterization of both myocardial extracellular volume expansion and myocyte mypertrophy by CMR detect early signs of myocardial tissue remodeling in Friedreich's ataxia patients without heart failure.
  • DOI:
    10.1186/1532-429x-18-s1-w7
  • 发表时间:
    2016-01-27
  • 期刊:
  • 影响因子:
  • 作者:
    Otavio R Coelho-Filho;Ravi V Shah;Thiago D Venancio;Alberto R Martinez;Tomas G Neilan;Irene Righetti;Cynthia B da Silva;Ingrid Faber;Iscia Lopes-Cendes;Marcondes França;Michael Jerosch-Herold
  • 通讯作者:
    Michael Jerosch-Herold

Tomas G Neilan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Tomas G Neilan', 18)}}的其他基金

Immune checkpoint inhibitors and accelerated coronary atherosclerosis
免疫检查点抑制剂与加速冠状动脉粥样硬化
  • 批准号:
    10436532
  • 财政年份:
    2022
  • 资助金额:
    $ 12.31万
  • 项目类别:
Immune checkpoint inhibitors and accelerated coronary atherosclerosis
免疫检查点抑制剂与加速冠状动脉粥样硬化
  • 批准号:
    10612938
  • 财政年份:
    2022
  • 资助金额:
    $ 12.31万
  • 项目类别:
Cardiovascular Diseases among Patients with Cancer and Patients living with HIV
癌症患者和艾滋病毒感染者的心血管疾病
  • 批准号:
    10322049
  • 财政年份:
    2020
  • 资助金额:
    $ 12.31万
  • 项目类别:
Cardiovascular Diseases among Patients with Cancer and Patients living with HIV
癌症患者和艾滋病毒感染者的心血管疾病
  • 批准号:
    10078978
  • 财政年份:
    2020
  • 资助金额:
    $ 12.31万
  • 项目类别:
Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins
HIV 心脏功能障碍的机制和他汀类药物的作用
  • 批准号:
    9906261
  • 财政年份:
    2017
  • 资助金额:
    $ 12.31万
  • 项目类别:
STOP-CA: Statins to prevent Cardiotoxicity from Anthracyclines
STOP-CA:他汀类药物可预防蒽环类药物的心脏毒性
  • 批准号:
    9351286
  • 财政年份:
    2016
  • 资助金额:
    $ 12.31万
  • 项目类别:
STOP-CA: Statins to prevent Cardiotoxicity from Anthracyclines
STOP-CA:他汀类药物可预防蒽环类药物的心脏毒性
  • 批准号:
    9176736
  • 财政年份:
    2016
  • 资助金额:
    $ 12.31万
  • 项目类别:

相似海外基金

The Clinical Relevance of Anthracycline-Related Cardiac Remodeling in Childhood Cancer Survivors
儿童癌症幸存者中蒽环类药物相关心脏重塑的临床意义
  • 批准号:
    10740728
  • 财政年份:
    2023
  • 资助金额:
    $ 12.31万
  • 项目类别:
Effects of Exercise on Changes in Cardiovascular Biomarkers in Patients with Breast Cancer During Anthracycline-based Chemotherapy
运动对蒽环类化疗期间乳腺癌患者心血管生物标志物变化的影响
  • 批准号:
    10579380
  • 财政年份:
    2023
  • 资助金额:
    $ 12.31万
  • 项目类别:
Deciphering the mutational basis of anthracycline-induced cardiotoxicity in childhood cancer survivors
破译蒽环类药物引起的儿童癌症幸存者心脏毒性的突变基础
  • 批准号:
    474425
  • 财政年份:
    2022
  • 资助金额:
    $ 12.31万
  • 项目类别:
    Studentship Programs
Dissecting mechanisms of anthracycline-induced cardiotoxicity
剖析蒽环类药物引起的心脏毒性机制
  • 批准号:
    10683784
  • 财政年份:
    2022
  • 资助金额:
    $ 12.31万
  • 项目类别:
Hemopexin as an Early Biomarker of Anthracycline Cardiac Toxicity
血红素结合蛋白作为蒽环类药物心脏毒性的早期生物标志物
  • 批准号:
    10593077
  • 财政年份:
    2022
  • 资助金额:
    $ 12.31万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 12.31万
  • 项目类别:
Mitochondria-Targeted Hydropersulfide Donors to Treat Anthracycline-Induced Cardiotoxicity
线粒体靶向氢过硫化物供体治疗蒽环类药物引起的心脏毒性
  • 批准号:
    10689759
  • 财政年份:
    2022
  • 资助金额:
    $ 12.31万
  • 项目类别:
Mitochondria-Targeted Hydropersulfide Donors to Treat Anthracycline-Induced Cardiotoxicity
线粒体靶向氢过硫化物供体治疗蒽环类药物引起的心脏毒性
  • 批准号:
    10798654
  • 财政年份:
    2022
  • 资助金额:
    $ 12.31万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 12.31万
  • 项目类别:
Deciphering the mutational basis of anthracycline-induced cardiotoxicity in childhood cancer survivors
破译蒽环类药物引起的儿童癌症幸存者心脏毒性的突变基础
  • 批准号:
    475540
  • 财政年份:
    2022
  • 资助金额:
    $ 12.31万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了